What are the indications, dosing schedule, administration route, premedication, monitoring, and contraindications for daratumumab in the treatment of multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Daratumumab for Multiple Myeloma

Daratumumab is a CD38-targeting monoclonal antibody administered intravenously at 16 mg/kg or subcutaneously at 1800 mg, indicated for multiple myeloma across various treatment lines—from newly diagnosed patients (in combination regimens) to heavily pretreated relapsed/refractory disease (as monotherapy after ≥3 prior therapies). 1, 2

Indications

Daratumumab is FDA-approved for multiple clinical scenarios in multiple myeloma:

Newly Diagnosed Multiple Myeloma

  • Transplant-eligible patients: Combined with bortezomib, lenalidomide, and dexamethasone (dara-VRd) or with bortezomib, thalidomide, and dexamethasone 3, 2
  • Transplant-ineligible patients: Combined with lenalidomide and dexamethasone or bortezomib and dexamethasone 2

Relapsed/Refractory Multiple Myeloma

  • After ≥1 prior therapy: Combined with bortezomib and dexamethasone (CASTOR trial showed 83% vs 63% ORR, PFS not reached vs 7.14 months) 4 or with lenalidomide and dexamethasone (POLLUX trial showed 93% vs 76% ORR, PFS not reached vs 18.4 months) 4
  • After ≥2 prior therapies: Combined with pomalidomide and dexamethasone (for patients who received lenalidomide and a proteasome inhibitor) 2
  • After ≥3 prior therapies: As monotherapy for patients who received a proteasome inhibitor and immunomodulatory agent, or who are double-refractory to both 1, 2

The monotherapy indication showed 29.2% ORR with median response duration of 7.4 months and 65% estimated 1-year overall survival in heavily pretreated patients 1.

Dosing Schedule and Administration

Intravenous Formulation

  • Dose: 16 mg/kg actual body weight 2
  • Schedule:
    • Weekly for cycles 1-2 (weeks 1-8)
    • Every 2 weeks for cycles 3-6 (weeks 9-24)
    • Every 4 weeks thereafter until disease progression 4, 2
  • First infusion time: Median 7 hours 5

Subcutaneous Formulation

  • Dose: 1800 mg fixed dose 5
  • Schedule: Same frequency as IV formulation
  • Administration time: 3-5 minutes 5
  • Advantages: Significantly shorter administration time, lower infusion-related reaction rates (median first dose <10% vs 50% for IV), lower infusion volume (15 mL vs 500-1000 mL) 5

The subcutaneous formulation achieves similar or greater serum concentrations compared to IV dosing with comparable efficacy and safety 5.

Premedication Requirements

Mandatory premedication before each infusion 2:

  • Corticosteroids: Reduce infusion-related reactions
  • Antipyretics: Typically acetaminophen
  • Antihistamines: Both H1 and H2 blockers

Post-infusion medications are also required 2.

Critical Monitoring Parameters

Before Treatment Initiation

  • Type and screen: Must be performed before starting daratumumab, as the drug binds to CD38 on red blood cells, causing false-positive indirect Coombs tests and interfering with blood compatibility testing for up to 6 months after the last dose 3, 2
  • Inform blood banks: All transfusion services must be notified that the patient is receiving daratumumab 2

During Treatment

  • Complete blood counts: Monitor periodically for neutropenia, thrombocytopenia, and anemia 2
  • Infection surveillance: Neutropenic patients require close monitoring for signs of infection 2
  • Response assessment considerations: For IgG kappa myeloma patients, daratumumab (an IgG kappa antibody) can produce spurious positive immunofixation results—use mass spectrometry-based assessment or special interference testing to differentiate therapeutic antibody from M-protein 3

Adverse Effects and Management

Infusion-Related Reactions

  • Incidence: 42.5% with IV monotherapy (mostly grade 1/2), predominantly during first infusion 1
  • Timing: 92% occur only with first infusion 4
  • Symptoms: Shortness of breath, cough, throat irritation, runny nose, fever, chills, nausea, vomiting, hypotension, hypertension 2
  • Management: Interrupt infusion for any severity; permanently discontinue for anaphylaxis or life-threatening reactions 2

Hematologic Toxicities

  • Neutropenia: Common; dose delays may be required for recovery 2
  • Thrombocytopenia: 54% in CASTOR trial; monitor and delay dosing as needed 4, 2
  • Anemia: 33% in monotherapy studies 1

Infections

  • Upper respiratory tract infections: Increased risk, particularly with combination regimens 4
  • Pneumonia: Higher risk with daratumumab-based regimens 6

Other Common Adverse Events (≥20%)

Fatigue, peripheral edema, nausea, diarrhea, constipation, cough, pyrexia, dyspnea, peripheral sensory neuropathy 2.

Contraindications

Absolute contraindication: History of severe hypersensitivity to daratumumab or any formulation component 2.

Special Populations and Considerations

Elderly and Frail Patients

Prolonged steroid use can be detrimental in frail patients ≥60 years—reduce dexamethasone to 20 mg weekly and discontinue with treatment response plateau or toxicity 3.

Renal Dysfunction

Not a contraindication to treatment 3.

Pregnancy

Embryo-fetal toxicity: Can cause fetal harm; advise pregnant women of risks and counsel females of reproductive potential to use effective contraception 2.

Clinical Efficacy Highlights

The addition of daratumumab to standard regimens consistently demonstrates:

  • 61-70% reduction in risk of progression or death in relapsed/refractory settings 4
  • Doubled depth of response (VGPR rates: 59% vs 29% in CASTOR; 76% vs 44% in POLLUX) 4
  • Benefit independent of cytogenetic risk groups 4

Common Pitfalls to Avoid

  1. Failing to type and screen before treatment: This creates delays in emergency transfusions later
  2. Not informing blood banks: Transfusion services must know about daratumumab therapy
  3. Misinterpreting immunofixation in IgG kappa patients: The therapeutic antibody can be mistaken for disease progression
  4. Inadequate premedication: Increases risk of severe infusion reactions
  5. Continuing full-dose steroids in elderly patients: Taper dexamethasone to 20 mg weekly in frail patients ≥60 years

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.